David Bredt Biography and Net Worth

Insider of Rapport Therapeutics

David brings over 20 years of neuroscience drug discovery experience to Rapport. He led groundbreaking research in receptor-associated protein biology at Janssen, where he served as Global Head of Neuroscience Discovery from 2011 through 2021. Prior to joining Janssen he was Vice President of Neuroscience at Eli Lilly and Company from 2004 to 2011. He was professor of physiology at the University of California, San Francisco for ten years. David received his A.B. in Chemistry from Princeton University, and his M.D. and Ph.D. from the Johns Hopkins School of Medicine. He worked as a postdoctoral fellow in the Department of Neuroscience at Johns Hopkins. He was elected to the Johns Hopkins University Society of Scholars in 2005.

What is David Bredt's net worth?: The estimated net worth of David Bredt is at least $10.64 million as of January 15th, 2026. Bredt owns 395,575 shares of Rapport Therapeutics stock worth more than $10,635,034 as of February 6th. This net worth evaluation does not reflect any other assets that Bredt may own. Learn More about David Bredt's net worth.
How do I contact David Bredt?: The corporate mailing address for Bredt and other Rapport Therapeutics executives is , , . Rapport Therapeutics can also be reached via phone at (857) 321-8020 and via email at [email protected]. Learn More on David Bredt's contact information.
Has David Bredt been buying or selling shares of Rapport Therapeutics?: During the last quarter, David Bredt has sold $228,140.00 in shares of Rapport Therapeutics stock. Most recently, David Bredt sold 8,500 shares of the business's stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $26.84, for a transaction totalling $228,140.00. Following the completion of the sale, the insider now directly owns 395,575 shares of the company's stock, valued at $10,617,233. Learn More on David Bredt's trading history.
Who are Rapport Therapeutics' active insiders?: Rapport Therapeutics' insider roster includes David Bredt (Insider), Abraham Ceesay (CEO), Cheryl Gault (COO), James Healy (Director), Troy Ignelzi (CFO), Krishnaswamy Yeleswaram (Insider), and Wendy Young (Director). Learn More on Rapport Therapeutics' active insiders.
Are insiders buying or selling shares of Rapport Therapeutics?: During the last year, Rapport Therapeutics insiders bought shares 3 times. They purchased a total of 19,400 shares worth more than $240,350.00. During the last year, insiders at the sold shares 20 times. They sold a total of 193,991 shares worth more than $4,933,186.08. The most recent insider tranaction occured on January, 20th when CEO Abraham Ceesay sold 5,833 shares worth more than $152,357.96. Insiders at Rapport Therapeutics own 13.6% of the company. Learn More about insider trades at Rapport Therapeutics.
Information on this page was last updated on 1/20/2026.

David Bredt Insider Trading History at Rapport Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/15/2026	Sell	8,500	$26.84	$228,140.00	395,575
12/31/2025	Sell	6,567	$30.05	$197,338.35	404,075
12/15/2025	Sell	8,500	$30.02	$255,170.00	392,642
11/17/2025	Sell	8,500	$25.19	$214,115.00	401,142
10/15/2025	Sell	8,500	$25.79	$219,215.00	409,642
8/15/2025	Sell	8,500	$15.00	$127,500.00	426,642
7/15/2025	Sell	8,500	$14.00	$119,000.00	435,142
7/15/2025	Sell	8,500	$14.00	$119,000.00	435,142

David Bredt Buying and Selling Activity at Rapport Therapeutics

Rapport Therapeutics Company Overview

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Today's Range

Now: $27.14

$26.16

$27.60

50 Day Range

MA: $28.46

$25.55

$31.90

2 Week Range

Now: $27.14

$6.43

$42.27

Volume

223,870 shs

Average Volume

342,169 shs

Market Capitalization

$1.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63